Urology

The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.

PRIORITY PRESS - 39th Annual Congress of the European Society for Medical Oncology (ESMO)

Survival Data Justify Early Use of Androgen Pathway Inhibitor in Metastatic Castration Resistant Prostate Cancer

Madrid, Spain / September 26-30, 2014

Madrid - The final overall survival (OS) results of a phase 3 multicentre trial have confirmed the value of first-line androgen inhibition in metastatic castration resistant prostate cancer (mCRPC). In the study, early use of an androgen...

PRIORITY PRESS - 2014 Genitourinary Cancers Symposium

Cardiovascular Risk with ADT for Advanced Prostate Cancer

San Francisco, California / January 30-February 1, 2014

San Francisco - The principal goal of androgen deprivation therapy (ADT) is to reduce testosterone to castrate levels, thereby depriving prostate cancer cells of their key growth substrate. However, several studies have shown that ADT...

PRIORITY PRESS - ECCO-17 - 38th ESMO Multidisciplinary Congress

Improving the Journey for Men with Metastatic Castrate Resistant Prostate Cancer

Amsterdam, The Netherlands / September 27-October 1, 2013

Amsterdam - Prostate cancer (PC) remains the most commonly diagnosed cancer in males and it is the second leading cause of death in men. Skeletal complication is the most important morbidity point in terms of metastases in PC and almost all...

PHYSICIAN PERSPECTIVE - Viewpoint based on presentations from the 108th Annual Meeting of the American Urological Association

New Oral Oncolytics: Major Step Forward in the Management of Metastatic Castrate-Resistant Prostate Cancer

San Diego, California / May 4-8, 2013

Reviewed and edited by:  Fred Saad, MD, FRCSProfessor and Chief of Urology Director of Urologic OncologyU of M Endowed Chair in Prostate CancerUniversity of Montreal Hospital CentreUniversité de MontréalMontreal,...

PHYSICIAN PERSPECTIVE - Viewpoint based on literature review

Options for Extending Survival in Advanced Colorectal Cancer: Increasing Evidence for a Chronic Therapy Approach

December 2012

Reviewed and Edited by:Sharlene Gill, MD, MPH, FACP, FRCPCGastrointestinal Medical OncologistBC Cancer AgencyAssociate Professor of MedicineUniversity of British ColumbiaVancouver, British Columbia Introduction Monoclonal antibodies...

PRIORITY PRESS - 4th European Multidisciplinary Meeting on Urological Cancers (EMUC 2012)

Targeting the Androgen Receptor in Castrate-resistant Prostate Cancer: A Step Forward

Barcelona, Spain / November 16-18, 2012

Barcelona - In prostate cancer, medical or surgical androgen ablation therapy leads to tumour regression and a rapid decline in prostate-specific antigen (PSA). However, progression of the cancer despite castrate levels of testosterone is a...

PRIORITY PRESS - 37th European Society of Medical Oncology Congress (ESMO)

Exploring Benefits of Multitargeted Therapy for Metastatic Colorectal Cancer and Gastrointestinal Stromal Tumours

Vienna, Austria / September 28 – October 2, 2012

Vienna - Progress continues to occur in the treatment of metastatic colorectal cancer. Improved recognition of the complexities of tumour signalling networks have led to the realization that inhibition of a single pathway is unlikely to...

PRIORITY PRESS - 48th Annual Meeting of the American Society of Clinical Oncology

Targeting Androgen Signalling in Metastatic Castration-resistant Prostate Cancer

Chicago, Illinois / June 1-5, 2012

Chicago - Improved understanding of the mechanisms of castration-resistant prostate cancer (CRPC) has led to the recognition of the key role the androgen receptor (AR) has in disease progression. Accumulating evidence suggests that AR...

PRIORITY PRESS - 48th Annual Meeting of the American Society of Clinical Oncology

Hormone Activity Suppression in Castration-resistant Prostate Cancer

Chicago, Illinois / June 1-5, 2012

Chicago - A series of multicentre studies with agents that suppress hormone activity are expected to revise current management pathways in castration-resistant prostate cancer (CRPC). The 2 largest studies, testing different strategies in...

PRIORITY PRESS - 107th Annual Meeting of the American Urological Association

Bone-targeted Therapies for Patients with Advanced Prostate Cancer

Atlanta, Georgia / May 19-24, 2012

Atlanta - Most patients with advanced prostate cancer will experience at least one skeletal-related event (SRE) without bone-directed therapy. In men with castration-resistant disease, an intravenous bisphosphonate and an anti-RANK ligand...

PAGE 1 OF 8   1 2 3 4 5 6 7 8